GPP
ICPT

Great Point Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Great Point Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-601,322
Closed -$6.65M – 55
2023
Q2 		$6.65M Buy
+601,322
New +$8.38M 1.3% 26
2023
Q1 		– Sell
-528,850
Closed -$6.54M – 56
2022
Q4 		$6.54M Buy
528,850
+423,850
+404% +$6M 1.28% 29
2022
Q3 		$1.47M Buy
+105,000
New +$1.69M 0.35% 34

Other funds holding ICPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Great Point Partners's ICPT Position: Q3 2023 in Review

Great Point Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 601,322 shares — an estimated $6.65M sold.

Great Point Partners first reported a position in ICPT in Q3 2022 and held it in 3 quarters. The position peaked at $6.65M in Q2 2023. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

  • Great Point Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Great Point Partners sold 601,322 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $6.65M.
  • Great Point Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2022 and held it in 3 quarters.
  • Great Point Partners's Intercept Pharmaceuticals, Inc. position peaked at $6.65M in Q2 2023.
  • 146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on Great Point Partners's 13F filing for Q3 2023, filed 14 Nov 2023.